Home        Sitemap        Contact us 
Company Profile

Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting kinase signaling and nuclear receptor pathways - A target class in treating Inflammation, Autoimmune, Cancer, and Neurodegenerative diseases. The Arrien Pharmaceuticals successfully applied and applying its proprietary platform FFDD technology and discovered a pipeline of uniquely positioned pre-clinical stage programs for future treatment of Multiples Sclerosis (MS), Psoriasis, Cancer (Ovarian, Breast, Prostate, DLBCL, and Lung), Rheumatoid Arthritis (RA), and Parkinson's Diseases.

Arrien Pharmaceuticals FFDD technology is a Fragment-Based Drug Design typically involves empirical and structural data input assisting our Medicinal Chemists in early phase of lead-to-drug-lead design process. Arrien Pharmaceuticals cost-competent approach rapidly aid our scientific team in selecting pre-clinical candidate ready compounds.

Arrien Pharmaceuticals completed ARN-6039 Phase 1 clinical trials, and patnered this program with Boston Pharmaceuticals in 2017.

Arrien Pharmaceuticals SIK2/SIK3 inhibitor ARN-3261 IND enabling studies initiated, and anticipated to complete by Q2, 2018.

Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.